Completed PHASE4 INTERVENTIONAL 2-arm NCT00827840

Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

Paliperidone ER Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia: a Randomized, Open-label, Controlled Trial

Sponsor: Chonnam National University Hospital

Conditions Schizophrenia

Interventions Paliperidone ER Risperidone

Updated 6 times since 2017 Last updated: Dec 22, 2011 Started: Nov 30, 2008 Primary completion: Feb 28, 2011 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00827840, this PHASE4 trial focuses on Schizophrenia and remains completed. Sponsored by Chonnam National University Hospital, it has been updated 6 times since 2008, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chonnam National University Hospital
Janssen Korea, Ltd., Korea
Ministry of Health, Republic of Korea

Data source: Chonnam National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gwangju, South Korea